FDA Warning Letters to GLP-1 Telehealth Companies: What They Mean for You

What happened

On March 3, 2026, the FDA announced it had issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. It was the second large batch of its kind.

In June 2026 the agency issued another 25 warning letters to telehealth and weight-loss companies over compounded GLP-1 advertising claims. The FDA has also stated it has sent large volumes of correspondence to telehealth and pharmaceutical companies about misleading compounded GLP-1 advertising since September 2025.

The agency published dedicated guidance, "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs," setting out what it considers false or misleading in this space.

What the FDA objected to

Reading across the letters, the same handful of claims come up repeatedly. If you recognise them from a provider's website, you are looking at exactly what the FDA has been targeting.

• •Implying or stating that a compounded GLP-1 is FDA-approved, or describing the pharmacy's FDA registration in a way that suggests the drug was reviewed.
• •Presenting compounded semaglutide or tirzepatide as equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro.
• •Citing clinical trial results for the brand-name drugs as if they applied to a compounded formulation. They do not — the trials evaluated the manufacturer-developed products only.
• •Branding or page design that obscures the fact that a product is compounded at all.
• •Omitting or burying required risk information while promoting benefits.
• •The legal consequence is that the FDA considers the products misbranded under the Federal Food, Drug, and Cosmetic Act.

What a warning letter is — and is not

A company can receive a warning letter, fix the claims, and continue operating normally. Some do. What matters to you as a patient is whether the issue was addressed — which is why the close-out letter is the thing to look for.

Two verified examples

Abstract advice is less useful than seeing what an actual letter looks like. Both of these are published on FDA.gov and can be read in full.

• •Both letters concern website marketing claims, not findings about a specific batch of medication.
• •Neither had a published close-out letter at the time of this review, meaning the public record shows the issues as unresolved.
• •We document the MEDVi letter directly in our MEDVi review, and its rating on this site reflects it.
• •We have not published a recommendation page for 24HrDoc. A provider with an open warning letter is not something we will route readers toward.

How to check any provider in two minutes

• •Search the FDA warning letter database at fda.gov for the company's legal name — not just its brand name, since letters are addressed to the corporate entity.
• •Check whether a close-out letter has been published. A close-out means the FDA is satisfied the issue was corrected; no close-out means it is unresolved as far as the public record shows.
• •Read what the letter actually alleges. "Misleading marketing claims" and "contaminated product" are very different findings.
• •Check the date. A letter from 2024 that was closed out matters less than one from this year with no close-out.
• •Look at whether the company changed the language on its site afterward. Several companies quietly rewrote their claims following these letters.
• •Ask the company directly. A provider that responds openly about a warning letter is behaving better than one that pretends it does not exist.

What this means for choosing a provider

The enforcement wave has not made compounded GLP-1s illegal to sell, and it has not shut down the market. What it has done is make a provider's marketing language a usable signal about how carefully it operates.

The better programs now state plainly on their own pages that compounded medications are not FDA-approved and that brand-name trial data does not apply to them. That is not a legal disclaimer they added grudgingly — it is exactly what the FDA has been asking for, and it tells you the company reads its own compliance obligations seriously.

• •Prefer providers that say "compounded" plainly rather than burying it in a footer.
• •Be wary of any site citing a 15% or 20% weight-loss figure next to a compounded product without noting the trials studied the brand-name drug.
• •"FDA-registered pharmacy" is not "FDA-approved medication" — a registered facility can still make an unapproved product.
• •A provider willing to name its pharmacy, publish its exclusion criteria, and state its refund terms is showing you the things the FDA has been asking companies to be clear about.

If you're currently on a compounded GLP-1

A warning letter to your provider is not a reason to stop your medication abruptly. Stopping a GLP-1 is a clinical decision, and abrupt discontinuation has its own consequences including weight regain.

It is a good reason to have a conversation.

• •Ask your provider what the letter concerned and what they changed in response.
• •Ask which pharmacy compounds your medication, and whether that has changed.
• •Ask what happens to your prescription and price if they can no longer supply the compounded product.
• •Price the brand-name manufacturer self-pay channels — that gap narrowed considerably after 2025.
• •If your insurance covers a brand-name GLP-1, this is a good moment to revisit that option.

Frequently Asked Questions